Inhibitive effect of cremophor RH40 or tween 80-based self-microemulsiflying drug delivery system on cytochrome P450 3A enzymes in murine hepatocytes

Abstract

This study examined the effect of self-microemulsiflying drug delivery system (SMEDDS) containing Cremophor RH40 or Tween 80 at various dilutions on cytochrome P450 3A (CYP3A) enzymes in rat hepatocytes, with midazolam serving as a CYP3A substrate. The particle size and zeta potential of microemulsions were evaluated upon dilution with aqueous medium. In vitro release was detected by a dialysis method in reverse. The effects of SMEDDS at different dilutions and surfactants at different concentrations on the metabolism of MDZ were investigated in murine hepatocytes. The cytotoxicity of SMEDDS at different dilutions was measured by LDH release and MTT technique. The effects of SMEDDS on the CYP3A enzymes activity were determined by Western blotting. Our results showed that dilution had less effect on the particle size and zeta potential in the range from 1:25 to 1:500. The MDZ was completely released in 10 h. A significant decrease in the formation of 1′-OH-MDZ in rat hepatocytes was observed after treatment with both SMEDDS at dilutions ranging from 1:50 to 1:250 and Cremophor RH 40 or Tween 80 at concentrations ranging from 0.1% to 1% (w/v), with no cytotoxicity observed. A significant decrease in CYP3A protein expression was observed in cells by Western blotting in the presence of either Cremophor RH40 or Tween 80-based SMEDDS at the dilutions ranging from 1:50 to 1:250. This study suggested that the excipient inhibitor-based formulation is a potential protective platform for decreasing metabolism of sensitive drugs that are CYP3A substrates.

Keywords

midazolam / Cremophor RH40 / Tween 80 / cytochrome P450 3A / self-microemulsifying drug delivery systems

References

[1] GuengerichF.P.. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol, 1999, 39: 1-17

[2] De-WildtS.N., KearnsG.L., LeederJ.S., et al.. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet, 1999, 37(6): 485-505

[3] PifferiG., RestaniP.. The safety of pharmaceutical excipients. Farmaco, 2003, 58(5): 541-550

[4] JambhekarS., CasellaR., MaherT., et al.. The physico chemical characteristics and bioavailability of indome thacin from β-cyclodextrin, hydroxyethyl-β-cyclodextrin, and hydroxyethyl-β-cyclodextrin complexs. Int J Pharm, 2004, 270(1–2): 149-166

[5] RenX.H., MaoX., CaoL., et al.. Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransfor mation activity in vitro and in vivo. Eur J Pharm Sci, 2009, 36(4–5): 401-411

[6] GursoyR.N., BenitaS.. self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother, 2004, 58(3): 173-182

[7] Bravo GonzalezR.C., HuwylerJ., WalterI., et al.. Improved oral bioavailability of cyclosporine A in male wistar rats. comparison of a solutol HS 15 containing self-dispersing formulation and a microsuspension. Int J Pharm, 2002, 245(1–2): 143-151

[8] HoustonJ.B., CarlileD.J.. Incorporation of in vitro drug metabolism data into physiologically-based pharmacok inetic models. Toxicol In Vitro, 1997, 11(3): 473-478

[9] BlancharedN., RichertL., NotterB., et al.. Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. Eur J Pharm Sci, 2004, 23(2): 189-199

[10] BachmannK., ByersJ., GhoshR., et al.. Prediction of in vivo hepatic clearance from in vitro data using cryopreserved human hepatocytes. Xenobiotica, 2003, 33(5): 475-483

[11] ItoK., HoustonJ.B.. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res, 2004, 21(5): 785-792

[12] McGinnityD.F., SoarsM.G., UrbanowiczR.A., et al.. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos, 2004, 32(11): 1247-1253

[13] SilvaJ.M., MorinP.E., DayS.H., et al.. Refinement of an in vitro model for cytochrome P450 induction. Drug Metab Dispos, 1998, 26(5): 490-496

[14] Bravo-GonzalezR.C., HuwylerJ., BoessF., et al.. In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam. Biopharm Drug Dispos, 2004, 25(1): 37-49

[15] HigashikawaF., MurakamiT., KanedaT., et al.. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. J Pharm Pharmacol, 1999, 51(1): 67-72

[16] SeglenP.O.. Preparation of isolated rat liver cells. Methods Cell Biol, 1976, 13: 29-83

[17] KienhuisA.S., WortelboerH.M., MaasW.J., et al.. A sandwich-cultured rat hepatocyte system with increased metabolic competence evaluated by gene expression profiling. Toxicol In Vitro, 2007, 21(5): 892-901

[18] ChenY., LiG., WuX., et al.. Self-microemulsifying drug delivery system(SMEDDS) of vinpocetine: formulation development and in vivo assessment. Biol PharmBull, 2008, 31(1): 118-125

[19] AshingtonC.. Drug release from microdisperse systems: a critical review. Int J Pharm, 1990, 58(1): 1-12

[20] LuC., LiP., GallegosR., et al.. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos, 2006, 34(9): 1600-1605

[21] GershanikT., BenitaS.. Positively charged self-emulsifying oily formulation for improving oral bioavailability of progesterone. Pharm Develop Technol, 1996, 1: 147-157

[22] GershanikT., BenzenoS., BenitaS., et al.. Interaction of a self-emulsifying lipid drug delivery system with the everted rat intestinal mucosa as a function of droplet size and surface charge. Pharm Res, 1998, 15(6): 863-869

[23] RenX.H., MaoX.L., SiL.Q., et al.. Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm, 2008, 70(1): 279-288

[24] MountfieldR.J., SenepinS., SchleimerM., et al.. Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int J Pharm, 2000, 211(1–2): 89-92

[25] Da-SilvaM.E.F., MeirellesN.C.. Interaction of non-ionic surfactants with hepatic CYP in prochilodus scrofa. Toxicol In Vitro, 2004, 18(6): 859-867

[26] YunC.H., SongM., AhnT., KimH., et al.. Conformational change of cytochrome P 450 1A2 induced by sodium chloride. J Biol Chem, 1996, 271(49): 31312-31316

[27] HalpertJ.R.. Structural basis of selective cytochrome P450 inhibition. Annu Rev Pharmacol Toxicol, 1995, 35: 29-53

[28] Aranzazu-PartearroyoM., OstolazaH., GoñiF.M., et al.. Surfactant-induced cell toxicity and cell lysis. A study using B16 melanoma cells. Biochem Pharmacol, 1990, 40(6): 1323-1328

[29] KammW., JonczykA., JungT., et al.. Evaluation of absorption enhancement for a potent cyclopeptidic ανβ3-anatgonist in a human intestinal cell line (Caco-2). Eur J Pharm Sci, 2000, 10(3): 205-214

[30] LimY.P., KuoS.C., LaiM.L., et al.. Inhibition of CYP3A4 expression by ketoconazole is mediated by the disruption of pregnane X receptor, steroid receptor coactivator-1, and hepatocyte nuclear factor 4alpha interaction. Pharmacog enet Genomics, 2009, 19(1): 11-24

[31] FujitaT., YasudaS., KamataY., et al.. Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model. J Pharmacol Exp Ther, 2008, 327(2): 592-599

[32] BookoutA.L., JeongY., DownesM., et al.. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell, 2006, 126(4): 789-799

[33] ChawlaA., RepaJ.J., EvansR.M., et al.. Nuclear receptors and lipid physiology: Opening the X-files. Science, 2001, 294(5548): 1866-1870

[34] MeiQ., RichardsK., Strong-BasalygaK., et al.. Using real-time quantitative TaqMan RT-PCR to evaluate the role of dexamethasone in gene regulation of rat P-glycoproteins mdr1/1b and cytochrome P450 3A1/2. J Pharm Sci, 2004, 93(10): 2488-2496

[35] MakishimaM., LuT.T., XieW., et al.. Vitamin D receptor as an intestinal bile acid sensor. Science, 2002, 296(5571): 1313-1316